Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór złośliwy (czerniak stopnia IIIC lub IV albo inny rozległy nowotwór), który nie może być wyleczony operacyjnie i nie reaguje na standardowe leczenie
- •Potwierdzony na badaniu mikroskopowym wysoki poziom białka IL13Ralpha2 w guzie (wynik >= 50)
- •Wiek od 18 do poniżej 75 lat
- •Dobry stan ogólny pacjenta (ECOG 0 lub 1)
- •Co najmniej jeden mierzalny guz (widoczny na badaniach lub fotografiach)
- •Wystarczająca liczba białych krwinek (ANC >= 1 x 10^9 komórek/L)
- •Wystarczająca liczba płytek krwi (>= 75 x 10^9/L) i hemoglobiny (>= 9,5 g/dL)
- •Zgoda na procedurę pobrania białych krwinek (leukaferezę) i na udział w badaniu
✗ Disqualifies
- •Niemożność uzyskania wystarczającej liczby komórek T z pobranej krwi (nie dotyczy drugiej infuzji)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- March 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
City of Hope
Duarte, United States
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
Stanford Cancer Institute
Stanford, United States
Trial contact
Lucie M Cutler
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.